IMCTs in Russia: Prospects
In September issue of CenterWatch monthly – a leading western periodical on clinical trials featured an article by Dmitry Sharov, Director of OCT Group on the significance of Russia for international multicenter trials.
Talking about development of the clinical trials segment in Russia in the recent twenty years, Dmitry Sharov remarks that it was fueled by serious academic base and high population of treatment-naïve patients, and low cost of patient participation in clinical trials.
According to Mr. Sharov, it is also important that clinical trials conducted in Russia are regularly reviewed by FDA and demonstrate quality which outstrips developed countries. However, not all aspects of the new legislation are taken into account. According to Mr. Sharov, pharmaceutical companies should now start to prepare themselves for work according to the new procedures.
Mr. Sharov also suggested, that in the view of full-scale launch of the common EEU drug market in the near future Russia will attract more interest on the part of international pharmaceutical companies, as a significant region for IMCTs.